<DOC>
	<DOCNO>NCT00635765</DOCNO>
	<brief_summary>The purpose study assess safety profile C2L-OCT-01 PR additional 96-week period acromegalic patient complete C2L-OCT-01 PR-301 study .</brief_summary>
	<brief_title>Open Label Extension Study Evaluating Safety Biological Activity C2L-OCT-01 PR Acromegalic Patients</brief_title>
	<detailed_description />
	<mesh_term>Acromegaly</mesh_term>
	<criteria>â€¢Subjects complete 24week C2LOCT01 PR301 study Women childbearing potential take adequate contraception pregnant lactating Subjects experience clinically significant adverse event relate study medication C2LOCT01 PR301 study Subjects uncontrolled Diabetes type II Subjects sign symptom related tumor compression optical chiasm Subjects symptomatic cholelithiasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Acromegaly</keyword>
</DOC>